Could a simple hormone improve preeclampsia outcomes?

NCT ID NCT02989025

Recruiting now Disease control Sponsor: University of Mississippi Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether giving progesterone (17 OHPC) to pregnant women diagnosed with preeclampsia before 34 weeks can improve outcomes for both mother and baby. The study will enroll 60 participants at the University of Mississippi Medical Center. Researchers will monitor blood pressure and other health measures to see if the treatment helps manage the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: progesterone (17-hydroxyprogesterone caproate)
What this could lead to: If it works, this could point toward a way to manage preeclampsia in pregnancy, potentially improving health for both mother and baby.
What could go wrong: This is a small, early pilot study (Phase 2) with only 60 participants. It may not show clear benefits, and results may not apply to all cases of preeclampsia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREECLAMPSIA (PE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREECLAMPSIA (PE) PREGNANCY

Contacts and locations

Locations

Winfred L. Wiser Hospital
RECRUITING

Jackson, Mississippi, 39216, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.